Item 1.01. Entry into a Material Definitive Agreement.

Effective February 6, 2020, Innovate Biopharmaceuticals, Inc. (the "Company") and the holders of the Company's outstanding short-term common stock purchase warrants (each a "Warrant" and collectively the "Warrants"), originally issued March 18, 2019, amended the Warrants to extend the exercise period of each Warrant by six months. The Warrants, as amended, are exercisable for up to an aggregate of 4,181,068 shares of the Company's common stock, par value $0.0001 per share, until September 18, 2020. Except as specifically amended, all terms and conditions of each Warrant shall remain in full force and effect and shall not be affected by this amendment.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits

Exhibit No.        Description
                     Form of Amendment to Short-term Common Stock Purchase
Exhibit 4.1        Warrant, dated February 6, 2020

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses